Clinical Trial

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.

Study acronym: HOPE II
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-30; most recent amendment 2026-01-09.
Status change: Recruiting → Active, Not Recruiting 2025-12-31
Status change: Not Yet Recruiting → Recruiting 2025-01-02
Trial Details
NCT Number NCT06436274
Lead Sponsor Massachusetts General Hospital
Collaborators: University of Witwatersrand, South Africa, Botswana Harvard Health Partnership, Ministry of Health, Rwanda, Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Karolinska Institutet
Conditions Human Papilloma Virus, Hiv
Enrollment 778 participants
Start Date 2024-10-14
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-12